Clinical Trials Browser

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT04641078 2024-02-28

DART

Phase 2 Unknown

124 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT04176081 2024-01-24

SChLAP/IDC

Phase 2 Not yet recruiting

208 enrolled

BreastGenitourinary

Carcinoma, Intraductal, Noninfiltrating, Prostatic Neoplasms

NCT04737109 2023-11-13

ADDItion

Phase 1/2 Terminated

6 enrolled 9 charts

Genitourinary

Prostatic Neoplasms

NCT05771896 2023-09-14

CARE

Phase 3 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT05900973 2023-08-07

A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer

Phase 2 Unknown

19 enrolled

Genitourinary

Prostatic Neoplasms

NCT04136353 2023-07-28

DASL-HiCaP

Phase 3 Active not recruiting

1,100 enrolled

Genitourinary

Prostatic Neoplasms

NCT05249712 2023-01-03

Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer

Phase 2 Unknown

30 enrolled

Genitourinary

Prostatic Neoplasms

Clinical Trials

THUNDER

PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.

ANDARP

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer

SOGUG-PRINCIS

ExBAT

COAction

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

DIVINE

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

ARACOG

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

DECREASE

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

PICASSO

ProBio

PSA-DEEP02

Physical Function During ARSI Treatment

PEACE8

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)

ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Neoadjuvant Therapy of Darolutamide Plus ADT for High Risk Prostate Cancer

DAROTAXEL

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy in Prostate Cancer Patients With Lymph Node-positive After Radical Prostatectomy: A Prospective Observational Cohort Study

OLIGOMET

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

ALADDIN

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

DART

SChLAP/IDC

ADDItion

CARE

A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer

DASL-HiCaP

Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer